Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Inside the Clinic: Experts Highlight Molecular Complexities in MCL

May 13th 2022

Maher Albitar, MD, and Andre H. Goy, MD, share insights regarding molecular complexities in mantle cell lymphoma.

Ibrutinib-Based Combination Therapy Displays Superior Efficacy Vs Monotherapy in MCL

May 9th 2022

Ibrutinib-based combination therapy demonstrated a higher overall response rate and longer progression-free survival compared with ibrutinib alone in patients with relapsed/refractory mantle cell lymphoma.

COVID-19 Mortality Rates Rise With Hospitalization and Rituximab Treatment in MCL

May 6th 2022

The overall mortality rate for patients with mantle cell lymphoma who contract COVID-19 is high, and mortality rates rise significantly in patients who are hospitalized or enter intensive care units, according to findings from a retrospective study that were published in Hemasphere.

Rituximab Plus Bendamustine Proves Promising in Young Patients With MCL

May 5th 2022

The combination of bendamustine and rituximab plus autologous stem cell transplantation and maintenance rituximab was shown to be an effective first-line treatment with comparable outcomes to R-CHOP/R-DHAP plus ASCT and observation in young patients with transplant-eligible mantle cell lymphoma.

Dr. Dietrich on Optimizing Treatment Options for Patients in MCL

April 12th 2022

Martin Dietrich, MD, PhD, discusses optimizing treatment options for patients with mantle cell lymphoma.

Zanubrutinib Continues to Show Safety, Efficacy in Relapsed/Refractory MCL

April 8th 2022

Zanubrutinib monotherapy continues to demonstrate durable responses with an acceptable toxicity profile in patients with relapsed or refractory mantle cell lymphoma.

European Approval Sought for Ibrutinib Plus Bendamustine/Rituximab for Previously Untreated MCL

April 4th 2022

A Type II variation application seeking the approval of a new indication for ibrutinib plus bendamustine and rituximab in adult patients with previously untreated mantle cell lymphoma who are not candidates for autologous stem cell transplant has been submitted to the European Medicines Agency.

Dr. Dietrich on the Current Treatment Landscape of MCL

April 1st 2022

Martin Dietrich, MD, PhD, discusses the current treatment landscape of mantle cell lymphoma.

Folding CAR T-cell Therapy Into Relapsed/Refractory MCL Treatment

March 9th 2022

Treatment with the CD19-directed CAR T-cell therapy brexucabtagene autoleucel demonstrated significant activity, marked by high response rates and prolonged survival, in patients with relapsed mantle cell lymphoma in the pivotal ZUMA-2 trial.

Copanlisib Plus Ibrutinib Produces High Response Rate in Relapsed/Refractory MCL, But Limited by Additive Toxicity

March 8th 2022

Although the addition of copanlisib to ibrutinib resulted in a high overall response rate in patients with relapsed/refractory mantle cell lymphoma, the regimen was found to have additive toxicity, according to findings from a small phase 1 trial.

Higher Doses of Ibrutinib/Venetoclax Not Linked With Higher Responses in Relapsed/Refractory MCL

March 8th 2022

The combination of ibrutinib given at 420 mg and venetoclax at 200 mg elicited an objective response rate of 93.8% in patients with relapsed/refractory mantle cell lymphoma, according to results of a phase 1 dose-finding study.

Dr. Wang on Adverse Effects of BTK Inhibitors in MCL

March 1st 2022

Michael Wang, MD, discusses adverse effects associated with BTK inhibitors in patients with mantle cell lymphoma.

Dr. Wang on Potential Adverse Effects of Ibrutinib in MCL

February 24th 2022

Michael Wang, MD, discusses potential adverse effects associated with ibrutinib in patients with mantle cell lymphoma.

Dr. Wang on Sequencing Oral Agents in MCL

February 23rd 2022

Michael Wang, MD, discusses the sequencing of oral therapies in mantle cell lymphoma.

Dr. Wang on the Evolution of Ibrutinib in the Treatment Landscape of MCL

February 14th 2022

Michael Wang, MD, discusses the evolution of ibrutinib in the treatment landscape of mantle cell lymphoma.

Frontline Ibrutinib/Rituximab Produced Meaningful Response Rates in Indolent MCL

February 11th 2022

The combination of ibrutinib plus rituximab generated a high rate of complete response and undetectable minimal residual disease when used in the frontline treatment of patients with indolent clinical forms of mantle cell lymphoma, allowing for treatment interruption in most responders.

Ibrutinib/Rituximab Followed by R-HCVAD Shows Activity, Safety in Younger Patients With MCL

February 10th 2022

Induction treatment with ibrutinib and rituximab was safe and active in patients with mantle cell lymphoma aged 65 years or younger, allowing for fewer cycles of subsequent chemotherapy with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone thereby reducing toxicity.

Dr. Wang on the Evolving Treatment Landscape of MCL

February 9th 2022

Michael Wang, MD, discusses the evolving treatment landscape of mantle cell lymphoma.

Treatment Strategies for Relapsed/Refractory MCL Represent a Unique Challenge

February 8th 2022

Despite the breakthroughs in the development of therapeutic regimens for patients with mantle cell lymphoma, variability in treatment pathways presents a unique hurdle in determining the appropriate course of care following disease progression.

Dr. Phillips on the Current Role of Ibrutinib in MCL

February 3rd 2022

Tycel Jovelle Phillips, MD, discusses the current role of ibrutinib in mantle cell lymphoma.